Protease-activated receptors: New concepts in regulation of G protein-coupled receptor signaling and trafficking

被引:96
|
作者
Trejo, J [1 ]
机构
[1] Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Cardiovasc Biol Ctr,Dept Pharmacol, Chapel Hill, NC 27599 USA
关键词
D O I
10.1124/jpet.103.052100
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Most G protein-coupled receptors (GPCRs) are reversibly activated upon ligand binding. However, activation of protease-activated G protein-coupled receptors (PARs) occurs through an irreversible proteolytic event that results in the generation of a tethered ligand that cannot diffuse away. This unusual mode of PAR activation raises important questions regarding the mechanisms responsible for termination of receptor signaling. There are currently four members of the PAR family. Thrombin activates PAR1, PAR3, and PAR4, whereas multiple trypsin-like serine proteases activate PAR2. The regulation of signaling by PAR1 has been extensively studied, whereas considerably less is known about the other PARs. It has been demonstrated that rapid termination of PAR1 signaling is critical in determining the magnitude and kinetics of the cellular protease response. Therefore, elucidating the molecular mechanisms involved in the regulation of PAR signaling is essential to fully understand protease-mediated responses. Recent findings indicate that novel mechanisms contribute to PAR1 desensitization, internalization, and down-regulation. This review focuses on the intracellular mechanisms that regulate PAR signaling and the recent progress in developing inhibitors of PAR signaling.
引用
收藏
页码:437 / 442
页数:6
相关论文
共 50 条
  • [41] Regulation of cardiomyocyte protease-activated receptors (PARs) by cathepsin G
    Steinberg, SF
    Pak, ES
    Alcott, SG
    CIRCULATION, 1999, 100 (18) : 6 - 6
  • [42] Integrin regulation of receptor tyrosine kinase and G protein-coupled receptor signaling to mitogen-activated protein kinases
    Juliano, RL
    Aplin, AE
    Howe, AK
    Short, S
    Lee, JW
    Alahari, S
    REGULATORS AND EFFECTORS OF SMALL GTPASES, PT G: RAS FAMILY II, 2001, 333 : 151 - 163
  • [43] Allosteric and biased G protein-coupled receptor signaling regulation: potentials for new therapeutics
    Khoury, Etienne
    Clement, Stephanie
    Laporte, Stephane A.
    FRONTIERS IN ENDOCRINOLOGY, 2014, 5
  • [44] Signaling, desensitization, and trafficking of G protein-coupled receptors revealed by green fluorescent protein conjugates
    Barak, LS
    Zhang, J
    Ferguson, SSG
    Laporte, SA
    Caron, MG
    GREEN FLUORESCENT PROTEIN, 1999, 302 : 153 - 171
  • [45] Novel Mechanisms in the Regulation of G Protein-coupled Receptor Trafficking to the Plasma Membrane
    Tholanikunnel, Baby G.
    Joseph, Kusumam
    Kandasamy, Karthikeyan
    Baldys, Aleksander
    Raymond, John R.
    Luttrell, Louis M.
    McDermott, Paul J.
    Fernandes, Daniel J.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2010, 285 (44) : 33816 - 33825
  • [46] Protease-activated receptor (PAR), a novel family of G protein-coupled seven trans-membrane domain receptors: Activation mechanisms and physiological roles
    Kawabata, A
    Kuroda, R
    JAPANESE JOURNAL OF PHARMACOLOGY, 2000, 82 (03): : 171 - 174
  • [47] G protein-coupled receptors and proliferative signaling
    Smit, MJ
    Bakker, RA
    Burstein, ES
    G PROTEIN PATHWAYS, PT A, RECEPTORS, 2002, 343 : 430 - 447
  • [48] Biased signaling of protease-activated receptors
    Zhao, Peishen
    Metcalf, Matthew
    Bunnett, Nigel W.
    FRONTIERS IN ENDOCRINOLOGY, 2014, 5
  • [49] Variants of G protein-coupled receptors: a reappraisal of their role in receptor regulation
    Maggio, Roberto
    Fasciani, Irene
    Rossi, Mario
    Di Gregorio, Jacopo
    Pietrantoni, Ilaria
    Puca, Valentina
    Flati, Vincenzo
    Scarselli, Marco
    BIOCHEMICAL SOCIETY TRANSACTIONS, 2016, 44 : 589 - 594
  • [50] Trafficking and Signaling of G Protein-Coupled Receptors in the Nervous System: Implications for Disease and Therapy
    Bunnett, Nigel W.
    Cottrell, Graeme S.
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2010, 9 (05) : 539 - 556